Drug Discovery
By
Could GSK and Hengrui’s $12B Alliance Set a New Standard in China-Originated Drug Collaborations?
Key Highlights GSK Bets Big on Hengrui: A $12B Strategic Play Anchored in Respiratory InnovationIn a high-stakes bet…
Can IGC Pharma’s New AI Models Change Alzheimer’s Diagnosis and Drug Discovery for Millions?
New tools unveiled at AAIC 2025 aim to detect Alzheimer’s earlier and faster, even in low-resource settings Key…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
How Is GSK’s Robust Q2 2025 Growth Powering Next-Gen Specialty Medicines and Vaccine Innovation?
Key Highlights Specialty Medicines Fuel Strong Market MomentumGSK’s specialty portfolio, notably in Respiratory, Immunology & Inflammation (+10%) and…
Is Aidoc’s $150M Bet on CARE™ and aiOS™ Resetting the Future of Clinical AI for 100 Million Patients?
Key Highlights CARE™ Foundation Model Redefining Standards in Clinical AIAidoc’s CARE™ model—now backed by $150 million in new…
